Cao Yihai, Zhong Weide
Laboratory of Angiogenesis Research, Department of Microbiology, Tumor, and Cell Biology, Karolinska Institutet, 171 77 Stockholm, Sweden.
Biomed Pharmacother. 2007 Oct;61(9):534-9. doi: 10.1016/j.biopha.2007.08.009. Epub 2007 Sep 14.
Lymphatic endothelial cells (LECs) originally differentiated from venous endothelial cells express several specific makers that distinguish them from the blood vessels. Lymphangiogenesis, a complex process of sprouting of new lymphatic vessels, is regulated by multiple direct and indirect growth factors. Vascular endothelial growth factor-C (VEGF-C) is the most potent and selective lymphangiogenic factor that plays a crucial role in the establishment of the first lymphatic vessel during embryonic development and in mediating lymphatic metastasis. In addition to VEGF-C, recent studies show that a range of known tumor-produced angiogenic factors also stimulates lymphangiogenesis, suggesting complex and tight regulations of this process. These tumor-derived lymphangiogenic factors may either alone or jointly promote lymphatic metastasis. Understanding regulatory mechanisms of lymphangiogenesis is pivotal for development of lymphangiogenesis antagonists that might therapeutically be used for intervention of lymphatic metastasis.
淋巴内皮细胞(LECs)最初由静脉内皮细胞分化而来,表达多种使其区别于血管的特异性标志物。淋巴管生成是新淋巴管芽生的复杂过程,受多种直接和间接生长因子调控。血管内皮生长因子-C(VEGF-C)是最有效且具选择性的淋巴管生成因子,在胚胎发育过程中首个淋巴管的形成以及介导淋巴转移方面发挥关键作用。除VEGF-C外,近期研究表明,一系列已知的肿瘤产生的血管生成因子也可刺激淋巴管生成,提示该过程存在复杂且严格的调控。这些肿瘤源性淋巴管生成因子可能单独或共同促进淋巴转移。了解淋巴管生成的调控机制对于开发可能用于治疗性干预淋巴转移的淋巴管生成拮抗剂至关重要。